Have no drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit.

Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a protease inhibitor (PI) or a nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor (experimental or approved) is not allowed.

Be able to understand and follow with protocol requirements, instructions and protocol-stated restrictions.

Signed and dated written informed consent prior to study entry.

Exclusion criteria:

Detection of any CXC Receptor4-tropic (X4-tropic) virus, based on viral tropism test at screening.

Any drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit.

Active Class C AIDS-defining illness.

Laboratory abnormalities at screen.

Significant blood loss prior to study start.

Pregnant or breastfeeding women.

Additional qualifying criteria to be determined by the physician.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00104429